Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Ascelia Pharma AB (publ)
  6. News
  7. Summary
    ACE   SE0010573113

ASCELIA PHARMA AB (PUBL)

(ACE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Ascelia Pharma : receives conditional FDA acceptance for brand name Orviglance

08/10/2021 | 03:32am EST

Ascelia Pharma AB (publ) (ticker: ACE) today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted Orviglance® as the proposed brand name for manganese chloride tetrahydrate (Mangoral), the company's novel first-in-class MRI contrast agent for use in liver MR imaging in adults with severely impaired kidney function.

The name Orviglance was developed in accordance with FDA’s guidance for the submission and evaluation of proprietary names and the name selection included a research study of healthcare practitioners across the U.S. to ensure accurate prescription and safety interpretation of the name.

In addition, Orviglance previously received an invented name approval from the European Medicines Agency (EMA).

 “This is yet another important step towards making Orviglance available to patients as our U.S. and global commercialization preparations progress. We continue to focus on the completion of the ongoing Phase 3 program and subsequent regulatory submission, approval and launch of this first-in-class MRI contrast agent”, said Julie Waras Brogren, Chief Commercial Officer of Ascelia Pharma.

Orviglance (previously referred to as Mangoral), which entered pivotal clinical studies in 2020, has been granted an Orphan Drug Designation (ODD) by the FDA and is targeted patients with poor kidney function who undergo an MRI scan of the liver to detect cancer.

As part of the launch plans for Orviglance*, Ascelia Pharma opened its US office in New Jersey earlier this year.

*Trademark is registered in Europe and several other markets and submitted for registration in the US.

© Modular Finance, source Nordic Press Releases

All news about ASCELIA PHARMA AB (PUBL)
01:40pResults from Orviglance comparison study to gadolinium presented at RSNA 2021
AQ
11/30Nomination Committee appointed for AGM 2022 in Ascelia Pharma AB
AQ
11/04QUARTERLY REPORT Q3 2021 : Oncoral – entering clinical collaboration
AQ
11/04Ascelia Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended ..
CI
10/19ASCELIA PHARMA : Food Effect Study with Orviglance successfully completed
AQ
10/19Ascelia Pharma AB Completes Food Effect Study with Orviglance Successfully
CI
09/21ASCELIA PHARMA : Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the ..
AQ
09/21Ascelia Pharma Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the..
CI
09/20ASCELIA PHARMA AB(OM : ACE) added to S&P Global BMI Index
CI
09/13Certain Ordinary Shares of Ascelia Pharma AB are subject to a Lock-Up Agreement Ending ..
CI
More news
Financials
Sales 2020 - - -
Net income 2020 -98,7 M -10,9 M -10,9 M
Net cash 2020 183 M 20,1 M 20,1 M
P/E ratio 2020 -15,0x
Yield 2020 -
Capitalization 1 074 M 119 M 118 M
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees 12
Free-Float 84,0%
Chart ASCELIA PHARMA AB (PUBL)
Duration : Period :
Ascelia Pharma AB (publ) Technical Analysis Chart | ACE | SE0010573113 | MarketScreener
Technical analysis trends ASCELIA PHARMA AB (PUBL)
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 31,90 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Magnus Olafsson Corfitzen Chief Executive Officer
Kristian Borbos Chief Financial Officer
Peter James Arthur Benson Chairman
Carl Bjartmar Chief Medical Officer
Bo Jesper Hansen Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ASCELIA PHARMA AB (PUBL)-43.88%117
MODERNA, INC.237.35%142 893
LONZA GROUP AG30.63%59 859
IQVIA HOLDINGS INC.44.63%49 504
SEAGEN INC.-8.64%29 257
CELLTRION, INC.-41.09%23 827